ThromboGenics, Bicycle Therapeutics enter exclusive agreement covering new approach to DME treatment

ThromboGenics has acquired exclusive rights to develop and commercialize treatments based on Bicycle Therapeutics’ bicyclic peptides that may offer the potential to improve treatment of diabetic macular edema, according to a news release. The companies will work together on preclinical development of the bicyclic peptide inhibitors as part of the collaboration and license agreement, the release said.

Full Story →